Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Small Lymphocytic JCAR017 chimeric antigen receptor CLL SLL chronic lymphocytic leukemia small lymphocytic lymphoma CAR CAR T cells autologous T cell therapy immunotherapy Lymphoma Leukemia Leukemia, Lymphoid JCAR017 (lisocabtagene maraleucel) JCAR017 (lisocabtagene maraleucel) + ibrutinib
Lead Scientists at UC Health
- Thomas J Kipps, MD, PhD (ucsd)
Thomas Kipps, MD, PhD, is Professor of Medicine, Evelyn and Edwin Tasch Chair in Cancer Research, and Deputy Director of Research Operations at the UC San Diego Moores Cancer Center. He received his Ph.D. in Immunology and M.D. from Harvard University and had his residency and fellowship training in Internal Medicine, Hematology, and Genetics at Stanford University.
- Herbert Eradat, MD, MS (ucla)
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 16 research publications.
- Lawrence Kaplan, MD (ucsf)
Professor, Medicine. Authored (or co-authored) 62 research publications.
- accepting new patients
- Start Date
- Completion Date
- Juno Therapeutics, a Subsidiary of Celgene
- Phase 1/2
- Study Type
- Last Updated